N/A
Manufactured by Janssen Products, LP
39,177 FDA adverse event reports analyzed
Last updated: 2026-04-14
ERYTHROPOIETIN is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Janssen Products, LP. The most commonly reported adverse reactions for ERYTHROPOIETIN include DEATH, ANAEMIA, FATIGUE, HAEMOGLOBIN DECREASED, ASTHENIA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for ERYTHROPOIETIN.
Out of 20,174 classified reports for ERYTHROPOIETIN:
The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.
Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.
This profile reflects 39,177 FDA FAERS reports that mention ERYTHROPOIETIN. Reporting is voluntary and does not prove that the drug caused any listed event.
Frequently reported terms in FAERS include DEATH, ANAEMIA, FATIGUE, HAEMOGLOBIN DECREASED, ASTHENIA, DIARRHOEA. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.
Labeling and FAERS entries often list Janssen Products, LP in connection with ERYTHROPOIETIN. Always verify the specific product and NDC with your pharmacist.